By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

People who have tried medication to lower their dangerously high levels of cholesterol and other blood fats – without success ...

Older adults face unique barriers in hypertension management, including comorbidities, mobility limitations, and medication adherence challenges, impacting digital health tool effectiveness. Trials ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

Dementia prevention is a critical area of research, as experts want to understand what people can do to decrease dementia risk. A recent study found that more than 5 years of taking medications like ...

People with type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a ...

Prophylactic cardiac treatment in DMD patients is associated with a 54% lower hazard of death, highlighting its potential survival benefit. Only 27.7% of DMD patients received prophylactic cardiac ...

MIT engineers have developed a flexible drug-delivery patch that can be placed on the heart after a heart attack to help ...

Metoprolol, acebutolol, and propranolol are heart medications linked to weight gain. Other heart medications may cause weight gain, but some might cause weight loss or be weight neutral. Many ...